Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, March 28, 2024 | Back issues
Courthouse News Service Courthouse News Service

$10.3 Billion Merger

Kite Pharma is selling itself too cheaply through an unfair process to Gilead Sciences, for $180 a share or $10.3 billion, shareholders say in a federal class action.

LOS ANGELES — Kite Pharma is selling itself too cheaply through an unfair process to Gilead Sciences, for $180 a share or $10.3 billion, shareholders say in a federal class action.

Categories / Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...